As shown in Fig. 2b, gefitinib treatment suppressed EGF-induced ERK1/2 phosphorylation and both Sp1 and DPD expression only in gefitinib-sensitive NSCLC cell lines PC9 and HCC827. The gene discussed is EGF; the disease is non-small cell lung carcinoma.